Thank you for your reply.
I'm just worried now that autifony won't work for me
Retigabine and AUT are different molecules targeted at different sites, the IC50 ("effectiveness") of both will not be the same, the maximum tolerable dosage of AUT is still unknown but it looks like it'll be safer and with less side effects. At the end, it's all about biochemistry, you have a small molecule interacting with a protein, the specifics of the interaction are exquisitely controlled and by no means two different molecules will have the same effect, plus AUT seems to be targeted at KCNQ3.x, while RTG is a "shotgun" approach.
I would expect less side effects with AUT, which means that we'll be able to take it at higher doses compared to RTG and achieve a better channel opening effect, then the expected repolarization will be achieved faster and with durable effects. And if it doesn't work, adding one atom here or there in the same molecule will help more. Don't forget that there's another molecule in development, SF34, which is essentially RTG with an added fluorine atom to increase its effectiveness, and it looks like would be, again, more potent, safer and better tolerated. For now, RTG, a "test molecule", is working for many people, I don't see why AUT, better targeted, more potent, better tolerated, wouldn't work the same way if not better. Then, the brain plasticity will do the rest.
Stay optimistic.